APA (7th ed.) Citation

BL, R., F, N., B, P., DR, P., JA, R., ML, R., . . . SC, R. (2009). CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. The American journal of pathology, 174(5), 1725. https://doi.org/10.2353/ajpath.2009.080241

Chicago Style (17th ed.) Citation

BL, Riser, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, and Riser SC. "CCN3 (NOV) Is a Negative Regulator of CCN2 (CTGF) and a Novel Endogenous Inhibitor of the Fibrotic Pathway in an in Vitro Model of Renal Disease." The American Journal of Pathology 174, no. 5 (2009): 1725. https://doi.org/10.2353/ajpath.2009.080241.

MLA (9th ed.) Citation

BL, Riser, et al. "CCN3 (NOV) Is a Negative Regulator of CCN2 (CTGF) and a Novel Endogenous Inhibitor of the Fibrotic Pathway in an in Vitro Model of Renal Disease." The American Journal of Pathology, vol. 174, no. 5, 2009, p. 1725, https://doi.org/10.2353/ajpath.2009.080241.